

ASX: CVB

14 August 2024

CLEANSING NOTICE – PLACEMENT

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “**CurveBeam AI**” or the “**Company**”) today gives notice under section 708(5)(e) of the *Corporations Act 2001* (Cth) (“**Corporations Act**”).

Background

On 1 August 2024, CurveBeam announced that it was undertaking a capital raising comprising a two tranche institutional placement, (“**Placement**”) and a 1-for-6 accelerated non-renounceable pro-rata entitlement offer (“**Entitlement Offer**”).

The Company has today issued:

- 11,111,112 new fully paid ordinary shares (“**New Shares**”) at an issue price of \$0.18 per New Share pursuant to the first tranche of the Placement; and
- 33,008,842 New Shares at an issue price of \$0.18 per New Share under the institutional component of the Entitlement Offer.

The Company seeks to rely on section 708A of the Corporations Act with respect to the sale of any New Shares issued under the first tranche of the Placement. These New Shares will rank equally with the existing fully paid ordinary shares on issue.

Statements by CurveBeam AI

CurveBeam AI relies on case 1 in section 708A(5) of the Corporations Act and gives notice that it has issued the New Shares under the first tranche of the Placement without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, CurveBeam AI:

- 1 has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
- 2 sections 674 and 674A of the Corporations Act; and
- 3 confirms that, there is no information:
 - a. that has been excluded from a continuous disclosure notice given to ASX in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:

For personal use only

- i. the assets and liabilities, financial position and performance, profits and losses and prospects of CurveBeam AI; and
- ii. the rights and liabilities attaching to CurveBeam AI's securities,

to the extent to which it would be reasonable for investors and their professional advisers to expect to find such information in a disclosure document.

Authorised for release by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au